drugset / Trial / NCT05385471
A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M in Healthy UK Adults
Non-randomizedParallel-groupOpen-labelPrevention
Summary
This is an open-label, single-centre Phase I P. falciparum blood-stage vaccine trial to assess the safety and immunogenicity and efficacy of the candidate malaria vaccines R78C and RH5.1 formulated in adjuvant Matrix-M
Timeline
- Start
- 2023-01-13
- Primary completion
- 2026-03-31
- Completion
- 2026-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | R78C | Vaccine | 10 ug | Intramuscular |
| Subject | RH5.1 | Vaccine | 10 ug | Intramuscular |
| Background | Matrix-M1 Adjuvant | Other / unclassified | 50 ug | Intramuscular |